Journal: Nanoscale

Article Title: Bioconjugates of photon-upconversion nanoparticles with antibodies for the detection of prostate-specific antigen and p53 in heterogeneous and homogeneous immunoassays.

doi: 10.1039/d5nr00176e

Figure Lengend Snippet: Fig. 1 (A) Schematic representation of bioconjugation of UCNPs with biomolecules: (1) ligand exchange reaction, replacing oleic acid residues with hydrophilic Cl−or BF4 −anions, (2) binding of the Ner-PEG-alkyne linker via the bisphosphonic group of neridronate, (3) copper(I)-catalyzed azide– alkyne cycloaddition (CuAAC) between the alkyne group on the UCNP surface and (3a) the azide-modified antibody or (3b) azide-modified streptavi- din. (B) The scheme of ULISA: (1) immobilization of the capture antibody onto the MTP surface, (2) binding of the analyte (antigen) to the capture antibody, and either (3a) binding of the UCNP–detection antibody conjugate or (3b) binding of the biotinylated detection antibody followed by (4) the UCNP–SA conjugate.

Article Snippet: Polyclonal anti-PSA antibody (AF1344), biotinylated polyclonal anti-PSA antibody (BAF1344), monoclonal anti-PSA antibody (MAB1344), polyclonal anti-p53 antibody (AF1355), biotinylated polyclonal anti-p53 antibody (BAF1355), monoclonal anti-p53 antibody (MAB1355), and p53 protein standard (SP450) were obtained from R&D Systems (USA).

Techniques: Binding Assay

Journal: Nanoscale

Article Title: Bioconjugates of photon-upconversion nanoparticles with antibodies for the detection of prostate-specific antigen and p53 in heterogeneous and homogeneous immunoassays.

doi: 10.1039/d5nr00176e

Figure Lengend Snippet: Fig. 3 Calibration curves obtained using Er-doped UCNPs conjugated with polyclonal antibodies in ULISA for (A) PSA and (B) p53. Error bars rep- resent the standard deviations of 3 independent wells. The dotted lines represent 3 times the standard deviation of the blank above the baseline of the regression curve, and their intersections with the respective fits correspond to the LODs.

Article Snippet: Polyclonal anti-PSA antibody (AF1344), biotinylated polyclonal anti-PSA antibody (BAF1344), monoclonal anti-PSA antibody (MAB1344), polyclonal anti-p53 antibody (AF1355), biotinylated polyclonal anti-p53 antibody (BAF1355), monoclonal anti-p53 antibody (MAB1355), and p53 protein standard (SP450) were obtained from R&D Systems (USA).

Techniques: Standard Deviation

Journal: International Journal of Nanomedicine

Article Title:

A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer

doi: 10.2147/ijn.s241324

Figure Lengend Snippet: Figure 4 CS-4D5/6e targets AKR1C3, and overexpression of AKR1C3 enhances the cytotoxic effect of CS-4D5/6e on cells. Percentage cell viability of (A) LNCAP cells cultured in normal and CSS media, (B) LNCaP-AKR1C3 cells cultured in normal, CSS, and CSS media supplemented with 10 nM Δ4-androstenedione after CS-4D5/6e treatment for 24 h. Percentage cell viability of (C) LNCAP cells cultured in normal and CSS media, (D) LNCaP-AKR1C3 cells cultured in normal, CSS, and CSS media supplemented with 10 nM Δ4-androstenedione after 6e treatment for 24 h. (E) Western blot analysis the expression of AKR1C3, PSA, and AR after LNCAP-AKR1C3 cells treated with CS-4D5/6e. Treatment with CS-4D5/6e at indicated concentration for 24 h in LNCaP-AKR1C3 cells cultured in CSS media. Abbreviations: CS, chemically chitosan; 4D5, single chain antibody fragment 4D5; 6e, a derivative of mansonone F; AD, androgen; CSS, charcoal-stripped serum; PSA, prostate specific antigen; AKR1C3, aldo-ketoreductase1C3; AR, androgen receptor; Ctr, control.

Article Snippet: Western Blotting Cells and tumor tissues were lysed in RIPA-1640 (Cell Signaling Technology) on ice for 30 min. After centrifugation at 12,000 rpm for 20min at 4°C, proteins were quantified and electrophoresed, as described previously.31 Cell membranes were probed with primary antibodies overnight against AR (rabbit monoclonal antibody (mAb); 5153S; Cell Signaling Technology), PSA (rabbit mAb; 5877S; Cell Signaling Technology), AKR1C3 (rabbit mAb; ab203834; Abcam, Cambridge, UK), HER2 (mouse mAb; bsm33051M; Bioss) or α-tubulin (rabbit mAb; A01080; Abbkine, Wuhan, China) followed by incubation with antimouse (AA75181; Bioworld Technology, Saint Louis Park, MN, USA) or anti-rabbit (AA01191; Bioworld Technology) horseradish peroxidase-conjugated secondary antibody (1:5000 dilution) for 1 h, followed by chemiluminescence International Journal of Nanomedicine 2020:15 submit your manuscript | www.dovepress.com DovePress 3091 In te rn at io na l J ou rn al o f N an om ed ic in e do w nl oa de d fr om h ttp s: //w w w .d ov ep re ss .c om / b y 19 3.

Techniques: Over Expression, Cell Culture, Western Blot, Expressing, Concentration Assay, Control

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Article Title: MicroRNA-340 Inhibits Esophageal Cancer Cell Growth and Invasion by Targeting Phosphoserine Aminotransferase 1.

doi: 10.1159/000430361

Figure Lengend Snippet: Fig. 4. PSAT1 is a direct target of miR-340. (A) The putative miR-340-binding sequence in the 3′-UTR of PSAT1 mRNA is shown. Muta tions were introduced into the PSAT1 3′-UTR sequence at the complementary site for the seed region of miR-340. (B) Luciferase reporter as says show the miR-340-me diated suppression of the ac tivity of the wild-type PSAT1 3′-UTR luciferase, but not the mutant 3′-UTR luciferase, in HEK-293 cells. (C) Ectopic ex pression of miR-340 in EC109 and EC7906 cells downregu lated the mRNA expression of PSAT1. (D) PSAT1, GSK- 3β, p-GSK-3β (Ser9), Snail, Vimentin and E-cadherin protein levels were deter mined by western blotting. *, p < 0.05; **, p < 0.01.

Article Snippet: The following antibodies were used: p-GSK-3β, GSK-3β, Snail, E-cadherin, Vimentin (Cell Signaling Technology); and PSAT1 (Proteintech Group Inc, Chicago, IL).

Techniques: Binding Assay, Sequencing, Luciferase, Mutagenesis, Expressing, Western Blot